

PATHFINDER: Interim Analysis of Avapritinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Daniel J. DeAngelo¹, Andreas Reiter², Deepti Radia³, Michael W. Deininger⁴, Tracy I. George⁵, Jens Panse⁶, Alessandro M. Vannucchi⁷, Madlen Jentzsch⁸, Iván Alvarez-Twose⁹, Andrzej Mital¹⁰, Olivier Hermine¹¹, Ingunn Dybedal¹², Elizabeth O. Hexner¹³, Lisa K. Hicks¹⁴, Lambert Span¹⁵, Ruben Mesa¹⁶, Prithviraj Bose¹⁷, Kristen M. Pettit¹⁸, Mark L. Heaney¹⁹, Stephen T. Oh²⁰, Jayita Sen²¹, Hui-Min Lin²¹, Brenton G. Mar²¹, Jason Gotlib²²

¹Dana-Farber Cancer Institute, Boston, MA, USA; ²University Hospital Mannheim, Heidelberg University, Mannheim, Germany; ³Guy's & St Thomas' NHS Foundation Trust, London, UK; ⁴University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA; ⁵ARUP Laboratories, University of Utah, Salt Lake City, UT, USA; ⁶University Hospital RWTH Aachen, Aachen, Germany; ⁷Center for Research and Innovation of Myeloproliferative Neoplasms – CRIMM, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy; ⁸Leipzig University, Leipzig, Germany; ⁹Institute of Mastocytosis Studies of Castilla-La Mancha, Spanish Reference Center of Mastocytosis, Toledo, Spain; ¹⁰Medical University of Gdansk, Gdansk, Poland; ¹¹Necker-Enfants Malades Hospital, Paris, France; ¹²Oslo University Hospital, Oslo, Norway; ¹³Abramson Cancer Center, University of Pennsylvania Philadelphia, PA, USA; ¹⁴St. Michael's Hospital, University of Toronto, Toronto, Canada; ¹⁵University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; ¹⁶Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA; ¹⁷The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ¹⁸University of Michigan, Ann Arbor, MI, USA; ¹⁹Columbia University Medical Center, New York, NY, USA; ²⁰Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA; ²¹Blueprint Medicines Corporation, Cambridge, MA, USA; ²²Stanford Cancer Institute/Stanford University School of Medicine, Stanford, CA, USA



Disclosure Information

Daniel J. DeAngelo, MD, PhD

I have the following financial relationships to disclose:

Consultant for:

Agios, Amgen, Autolus, Blueprint Medicines Corporation, Forty-Seven, Incyte Corporation, Jazz Pharmaceuticals, Novartis, Pfizer, Shire, and Takeda


Grant/Research support from:

AbbVie, Blueprint Medicines Corporation, GlycoMimetics, and Novartis

Avapritinib is not approved as safe or effective for use in systemic mastocytosis by the FDA, EMA, or any healthcare authority in any jurisdiction.

Advanced Systemic Mastocytosis (AdvSM) is a Rare Hematologic Neoplasm Driven by *KIT* D816V in ~95% of Cases

- Patients with AdvSM have elevated mast cell (MC) burden, organ damage and poor survival¹
- MC hyperactivation leads to severe mediator symptoms and poor quality of life¹
- Multikinase inhibitor midostaurin is the only approved therapy for all subtypes of AdvSM^a
 - ORR^b was 28% per IWG-MRT-ECNM criteria requiring resolution of organ damage^{2,c}
 - Median overall survival was 2.5 years³



Organ Damage (C-findings)

- Cytopenias
- Liver dysfunction
- Ascites, pleural effusions
- Splenomegaly with hypersplenism
- Malabsorption with weight loss
- Large osteolytic lesions

^aImatinib is approved by the U.S. FDA for the treatment of ASM without or unknown *KIT* D816V mutation status. ^bORR is defined as CR + PR + CI. ^cPost hoc IWG-MRT-ECNM analysis in midostaurin SmPC requiring resolution of organ damage for ≥ 12 weeks; ² per Valent criteria, which included lesser organ damage improvements for ≥ 8 weeks, ORR was 60%.³

1. Pardanani A. *Am J Hematol.* 2019;94:363–377; 2. RYDAPT (midostaurin). Summary of Product Characteristics. 2017; 3. Gotlib J et al. *N Engl J Med.* 2016;374:2530–2541.




ASM, aggressive systemic mastocytosis; CI, clinical improvement; CR, complete remission; IWG-MRT-ECNM, International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on Mastocytosis; ORR, overall response rate; PR, partial remission; SmPC, Summary of Product Characteristics.

Avapritinib, a Potent and Selective KIT D816V inhibitor, Induced Deep Reductions in MC Burden and Resolution of Organ Damage

- Highly potent on KIT D816V (biochemical $IC_{50}=0.27$ nM)

Phase 1 Dose Escalation/Expansion EXPLORER Study¹

- 75% ORR^a per modified IWG-MRT-ECNM criteria
- Responses were rapid, with complete remissions over time (median follow-up: 23 months)
- Improvements in mast cell burden, organ damage and patient symptoms and quality of life




Data cut-off: May 27, 2020. ^aORR is defined as CR + CRh + PR + CI.

1. Gotlib J et al. ASH 2020 [Oral 345]; 2. Gotlib J et al. EHA 2020 [Poster EP1079].

IC_{50} , half-maximal inhibitory concentration.

PATHFINDER Phase 2 Registrational Study

Avapritinib 200^a mg QD Starting Dose (Both Cohorts)



- Central diagnosis of AdvSM
- ≥18 years of age
- ECOG PS 0–3
- **Excluded:** Platelets $<50 \times 10^9/L$
(added in 2019 to reduce risk of intracranial bleeding)

Primary Endpoint (Cohort 1)

- Adjudicated ORR by modified IWG-MRT-ECNM criteria
- Interim analysis: Null hypothesis was 28% and a 1-sided type I error rate of 0.00625

Secondary Endpoints (Both Cohorts)

- Change in patient-reported symptoms (key secondary) and quality of life
- Change in disease burden
- Safety

^a60 patients received 200 mg and 2 patients received 100 mg. ^bPer modified IWG-MRT-ECNM criteria, response assessment requires ≥1 evaluable C-finding at baseline. MCL without an evaluable C-finding may be assessed for response based on disease burden alone (Gotlib et al. *Blood*. 2013;21:2393–2401). ^cPatients with sufficient follow-up for response assessment are on study ≥6 months (with ≥2 bone marrow assessments to allow for a confirmed response) or are off the study at any timepoint. ECOG PS, Eastern Cooperative Oncology Group Performance Status; MCL, mast cell leukemia; QD, once-daily.

Baseline Characteristics

	Safety Population (N=62)	Interim Analysis Efficacy Population (n=32)
Median age, years (range)	69 (31–88)	68 (37–85)
Female, n (%)	28 (45)	14 (44)
ECOG Performance Status 2–3, n (%)	19 (31)	11 (34)
AdvSM subtype per central assessment, n (%)		
ASM	9 (15)	2 (6)
SM-AHN	43 (69)	26 (81)
MCL	10 (16)	4 (13)
<i>KIT</i> D816V positive in blood, n (%)	59 (95)	30 (94)
<i>SRSF2/ASXL1/RUNX1</i> mutation positive, n (%)	26 (42)	17 (53)
Any prior anti-neoplastic therapy, n (%)	42 (68)	23 (72)
Midostaurin	34 (55)	17 (53)
Cladribine	8 (13)	4 (13)
BM biopsy MC burden, median percent (range)	45 (1–95)	50 (10–95)
Serum tryptase level, median ng/mL (range)	283 (24–1600)	293 (24–1600)

ASM, aggressive systemic mastocytosis; SM-AHN, systemic mastocytosis with associated hematologic neoplasm; BM, bone marrow.

Efficacy of Avapritinib 200 mg QD in Interim Analysis

Best Confirmed Response, n (%)	All AdvSM (n=32) ^a
Overall Response Rate (CR + CRh + PR + CI)	24 (75)
CR or CRh	6 (19)
Complete Remission (CR)	0
CR with partial hematologic recovery	6 (19)
Partial Remission (PR)	10 (31)
Clinical Improvement (CI)	8 (25)
Stable Disease (SD)	4 (13)
Progressive Disease (PD)	1 (3)
Not Evaluable (NE)	3 (9) ^b

Interim analysis: passed ($P=1.60 \times 10^{-9}$)

CRh (mIWG-MRT-ECNM) requires

- Full resolution of all evaluable C-findings
- BM MC aggregates eliminated
- Serum tryptase <20 ng/mL
- Resolution of palpable hepatosplenomegaly
- **Partial hematologic recovery**
 - ANC >0.5×10⁹/L with normal differential
 - Platelet count >50×10⁹/L
 - Hgb level >8.0 g/dL

PR requires

- Full resolution of ≥1 evaluable C-findings
- ≥50% reduction in BM MCs, serum tryptase

^aOne patient in the evaluable population started at 100 mg QD. ^bThree (9%) of 32 patients in the interim analysis were assessed as not evaluable for response due to coming off study for AE before 13 weeks. ANC, absolute neutrophil count; Hgb, hemoglobin.

Responses in All Subtypes of AdvSM, Regardless of Prior Therapy

Best Confirmed Response, n (%)	All AdvSM (n=32) ^a	AdvSM Subtype		
		ASM (n=2)	SM-AHN (n=26)	MCL (n=4)
Overall Response Rate (CR + CRh + PR + CI)	24 (75)	2 (100)	21 (81)	1 (25)
CR or CRh	6 (19)	1 (50)	5 (19)	0
Complete Remission (CR)	0	0	0	0
CR with partial hematologic recovery	6 (19)	1 (50)	5 (19)	0
Partial Remission (PR)	10 (31)	1 (50)	8 (31)	1 (25)
Clinical Improvement (CI)	8 (25)	0	8 (31)	0
Stable Disease (SD)	4 (13)	0	2 (8)	2 (50)
Progressive Disease (PD)	1 (3)	0	0	1 (25)
Not Evaluable (NE)	3 (9) ^b	0	3 (12)	0


^aOne patient in the evaluable population started at 100 mg QD. ^bThree (9%) of 32 patients in the interim analysis were assessed as not evaluable for response due to coming off study for AE before 13 weeks.

Responses in All Subtypes of AdvSM, Regardless of Prior Therapy

Best Confirmed Response, n (%)	All AdvSM (n=32) ^a	AdvSM Subtype			Any Prior Therapy	
		ASM (n=2)	SM-AHN (n=26)	MCL (n=4)	Yes (n=23)	No (n=9)
Overall Response Rate (CR + CRh + PR + CI)	24 (75)	2 (100)	21 (81)	1 (25)	17 (74)	7 (78)
CR or CRh	6 (19)	1 (50)	5 (19)	0	3 (13)	3 (33)
Complete Remission (CR)	0	0	0	0	0	0
CR with partial hematologic recovery	6 (19)	1 (50)	5 (19)	0	3 (13)	3 (33)
Partial Remission (PR)	10 (31)	1 (50)	8 (31)	1 (25)	7 (30)	3 (33)
Clinical Improvement (CI)	8 (25)	0	8 (31)	0	7 (30)	1 (11)
Stable Disease (SD)	4 (13)	0	2 (8)	2 (50)	2 (9)	2 (22)
Progressive Disease (PD)	1 (3)	0	0	1 (25)	1 (4)	0
Not Evaluable (NE)	3 (9) ^b	0	3 (12)	0	3 (13)	0

^aOne patient in the evaluable population started at 100 mg QD. ^bThree (9%) of 32 patients in the interim analysis were assessed as not evaluable for response due to coming off study for AE before 13 weeks.


Responses on Avapritinib Improved with Time




- With a median follow-up of 10.4 months all responses are still ongoing
- Median time to response was rapid (2 months) at 200 mg QD
- Responses maintained after dose reduction (92% of responders had a dose reduction to ≤100 mg)
- Patients' responses improved with more time with median time to CRh of 5.6 months

Each cycle is 28 days. C, cycle; D, day.

Avapritinib Led to Profound Reductions in Bone Marrow Mast Cells and Serum Tryptase




- 88% of patients achieved $\geq 50\%$ reduction in marrow mast cells
- 60% of patients achieved elimination of marrow mast cell aggregates




- 93% of patients achieved $\geq 50\%$ reduction in serum tryptase
- 43% of patients achieved reduction to <20 ng/mL

Avapritinib Led to Profound Reductions in *KIT* D816V Allele Fraction and Spleen Volume



- 60% of patients achieved $\geq 50\%$ reduction in VAF
- 35% of patients achieved VAF of < 1%



- 66% of patients achieved a $\geq 35\%$ reduction in spleen volume

VAF, variant allele fraction.

Adverse Events (Safety Population, N=62)

Adverse Events (AEs) in ≥15%	Any-cause AEs	
	Any Grade	Grade 3/4
Non-hematologic, n (%)		
Peripheral edema	31 (50)	2 (3)
Periorbital edema	30 (48)	2 (3)
Diarrhea	14 (23)	1 (2)
Nausea	11 (18)	1 (2)
Vomiting	11 (18)	1 (2)
Fatigue	9 (15)	2 (3)
Hematologic, n (%)		
Thrombocytopenia	28 (45)	10 (16)
Anemia	20 (32)	10 (16)
Neutropenia	15 (24)	15 (24) ^a

AE table includes pooled similar AE terms for periorbital edema, thrombocytopenia, anemia, and neutropenia.


^aFive (8%) patients had Grade 4 neutropenia. ^bConfusional state (n=3), memory impairment (n=3), and cognitive disorder (n=1). ^cCBC monitored every 2 weeks for the first 4 weeks, then at least every 4 weeks, or every 2 weeks if platelets <75×10⁹/L. If platelets <50×10⁹/L interrupt avapritinib and resume at lower dose when ≥50×10⁹/L. Avapritinib treatment with platelet growth factor support or recurrent platelet transfusions was allowed with Sponsor approval.

- 52 (84%) remain on treatment
- 3 (5%) discontinued due to treatment-related AE
- 42 (68%) had a dose reduction due to an AE, most commonly cytopenias
- No treatment-related deaths occurred
- Six patients had Gr 1 and one had Gr 2 cognitive AEs^b
- One (1.6%) patient had a subdural hematoma (Gr 4), associated with pre-existing severe thrombocytopenia (<50×10⁹/L), prior to exclusion of such patients
 - Subsequently excluded baseline severe thrombocytopenia, increased CBC monitoring, and modified dose guidance^c


Avapritinib Led to Rapid and Durable Reduction in SM Symptoms

Advanced Systemic Mastocytosis-Symptom Assessment Form (AdvSM-SAF): Validated patient-reported outcome tool in AdvSM^a

Significant Reduction in Total Symptom Score



Reduction in Individual Symptom Scores




^aTaylor F et al. 2019 ISPOR EU [Poster PRO143].

BL, baseline; C3, Cycle 3; C11, Cycle 11; TSS, total symptom score.

Avapritinib Led to Rapid and Durable Improvement in Quality of Life (QoL) and Functional Impairment

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ C30)



- AdvSM patients have poor QoL and functional impairment at Baseline
- Improvements in QoL approaching healthy controls
- Improvements in Physical, Role, Emotional, Cognitive and Social Functioning

^aBL (n=54); C3 (n=45); C11 (n=9). ^bReference mean EORTC-QLQ C30 scores from average of male and female 60–69 and ≥70-year-old cohorts from Hinz A et al. *Acta Oncologica*. 2014;53:958–965.



Avapritinib Reduced Disease Burden and Patient Symptoms

- Avapritinib with a starting dose of 200 mg QD induced rapid, durable, and improving responses, consistent with the phase 1 EXPLORER study
- ORR (CR + CRh + PR + CI) by mIWG-MRT-ECNM criteria was 75%, with all responses ongoing
- Reductions in disease burden (BM MCs, serum tryptase, *KIT* D816V VAF, and spleen volume)
- Significant reductions in symptom burden and improvements in quality of life
- Avapritinib was well tolerated with few patients discontinuing treatment due to related AEs

